Alcami’s St. Louis Facility Issued European Medicines Agency Certification
The company’s center of excellence for advanced analytical testing passed GMP inspection from the European Medicines Agency.
On April 29, 2019, Alcami announced that its St. Louis, MO, center of excellence for advanced analytical testing was issued a certificate of compliance by the European Medicines Agency (EMA) on April 23, 2019 following the facility’s recent successful GMP inspection.
The certification confirms the site is compliant with GMP laboratory storage and testing practices and enables the laboratory to process more commercial products for the European Union (EU). In September 2017, Alcami opened its center of excellence in St. Louis’s Cortex Innovation Community, a 200-acre innovation hub and technology district. The facility provides analytical testing services for manufacturers’ new drug entities, generics, animal health products, APIs, raw materials, in-process goods, medicated consumer health products, chemicals, and biologics. In May 2018, the site was honored by the Missouri House of Representatives and St. Louis Mayor Lyda Krewson with a resolution and letter of commendation recognizing the company’s operational excellence and accomplishments.
Source: Alcami
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
